SCHEMBL2186318

SCHEMBL2186318

CCOC(=O)c1sc(-c2cc(C#N)c3ccccc3c2)nc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.55
DBF4 Q9UBU7 3/20 0.55
LMNA P02545 1/20 0.52
XDH P47989 6/20 0.51
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 1/20 0.50
TRPM8 Q7Z2W7 4/20 0.49
ABCC4 O15439 1/20 0.46
ABCB11 O95342 1/20 0.46
PGR P06401 1/20 0.46
CHRM1 P11229 1/20 0.46
PDE4A P27815 1/20 0.46
BLVRB P30043 1/20 0.46
TARBP2 Q15633 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
DHODH Q02127 1/20 0.46
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185472 0.88 CDC7 (0.54) CDC7DBF4LMNAXDHKDM4E
SCHEMBL2185744 0.88 CDC7 (0.53) CDC7DBF4LMNAXDHKDM4E
SCHEMBL19919157 0.85 XDH (0.55) XDHKDM4EALDH1A1ABCC4ABCB11
SCHEMBL2185636 0.85 XDH (0.67) XDHKDM4EALDH1A1ABCC4ABCB11
SCHEMBL2186240 0.84 MEN1 (0.48) CDC7DBF4LMNAXDHKDM4E
SCHEMBL2184826 0.84 CDC7 (0.58) CDC7DBF4LMNAKDM4EALDH1A1
SCHEMBL1981415 0.82 CDC7 (0.54) CDC7DBF4LMNAXDHKDM4E
SCHEMBL469731 0.81 CDC7 (0.58) CDC7DBF4LMNAXDHKDM4E
SCHEMBL20195691 0.81 CDC7 (0.55) CDC7DBF4LMNAXDHKDM4E
SCHEMBL30804867 0.81 CDC7 (0.58) CDC7DBF4LMNAXDHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343279-B1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-8263622-B2 Fused-ring derivative and medical application of same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-25 US disclosed
EP-2343279-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME XDH, OAT, PON1 CDC7 3507/4885DBF4 3808/4885LMNA 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.